Skip to main content

Table 2 Clinical study of antitumor drugs targeting cAMP–PKA pathway (from clinicaltrials.gov)

From: Complex roles of cAMP–PKA–CREB signaling in cancer

Identifier Title Cancer type Locations
NCT00004902 Tocladesine in treating patients with recurrent or refractory multiple myeloma Multiple myeloma and plasma cell tumor Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States
NCT00021268 Tocladesine in treating patients with recurrent or progressive metastatic colorectal cancer Colorectal cancer Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States
NCT00004864 Docetaxel and GEM 231 in treating patients with recurrent or refractory solid tumors Unspecified adult solid tumor Albert Einstein Comprehensive Cancer Center
Bronx, New York, United States
NCT00004863 Paclitaxel and GEM 231 in treating patients with recurrent or refractory solid tumors Unspecified adult solid tumor Albert Einstein Comprehensive Cancer Center
Bronx, New York, United States